Skip Navigation
Skip to contents
Filter

ARTICLE TYPE

PUBLICATION DATE

12 results
Display

Liver Transplantation in Mixed Hepatocellular Carcinoma and Cholangiocarcinoma

Kim JM

Mixed hepatocellular carcinoma and cholangiocarcinoma (HCC-CC) are rare tumors, and the risk factors associated with them are not well understood yet. Moreover, the diagnosis of mixed HCC-CC can be complicated...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Malignant Hepatic Solitary Fibrous Tumor

Kim HI, In SK, Yi HS, Lee MJ, Kim HY

Hepatic solitary fibrous tumors (SFTs) are mostly benign and rare because of information regarding the clinical symptoms, treatment, and prognosis of their malignant forms is currently lacking. A literature review...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Contrast-enhanced Ultrasonography: The Third Modality for Differentiation of Liver Mass

Kang MK, Kim MY, Kang SH, Baik SK

Contrast-enhanced ultrasonography (CEUS) using microbubble ultrasonography contrast agent can show the vascular structure and unique contrast enhancement patterns of focal liver lesions, including hepatocellular carcinoma (HCC). CEUS shows three phases,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Radiation-induced Myositis after Proton Beam Therapy to Huge Hepatocellular Carcinoma

Kim J, Yoo GS, Sinn DH, Park HC, Koh KC

Proton beam therapy (PBT) is one of the advances in radiotherapy techniques, which enables dose escalation with lower probability of radiation-induced liver or gastrointestinal injuries. However, the chest wall proximal...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Early Onset Polymorphic Post-transplant Lymphoproliferative Disease Mimicking a Solitary Necrotizing Abscess in a Graft Liver

Sung PS, Lee J, Lee J, Nam HC, Bae SH, Yoon SK

Although post-transplantation lymphoproliferative disease (PTLD) after liver transplantation is very rare, its prognosis is worse than that of PTLD following other types of solid organ transplantation. Here, we report a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-term Disease-free Survival after Trimodality Treatment of Recurrent Hepatocellular Carcinoma Involving the Inferior Vena Cava and Right Atrium

Park S, Yoon WS, Yim HJ, Rim CH

Hepatocellular carcinoma (HCC) involving the inferior vena cava (IVC) and/or right atrium (RA) is a rare and intractable disease. A standard treatment has not been established yet, owing to the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hepatocellular Carcinoma with Segmental Portal Vein Invasion Exhibiting a Complete Response after Transarterial Radioembolization

Yoon JS, Yu SJ, Lee YB, Cho EJ, Lee JH, Kim YJ, Yoon JH

The treatment options available for patients with hepatocellular carcinoma (HCC) with portal vein invasion (PVI) include sorafenib, transarterial radioembolization (TARE), radiation therapy (RT), transarterial chemoembolization with RT, and proton beam...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Genomic Landscape and Its Clinical Implications in Hepatocellular Carcinoma

Yim SY, Lee JS

The pathogenesis of hepatocellular carcinoma (HCC) is a complex process. During the last decade, advances in genomic technologies enabled delineation of the genomic landscape of HCC, resulting in the identification...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

Cho YY, Choi YH, Yu SJ, Cho EJ, Lee JH, Kim YJ, Yoon JH

BACKGROUND/AIMS: Tenofovir disoproxil fumarate (TDF) is potentially nephrotoxic in chronic hepatitis B patients. Hepatocellular carcinoma (HCC) patients treated using transarterial chemoembolization (TACE) are at an increased risk of renal injury....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Sorafenib-induced Pancreatic Pseudocyst in a Patient with Advanced Hepatocellular Carcinoma: a Rare Adverse Event

Kim DH, Kim M, Yim HJ, Suh SJ, Jung YK

A 54-year old man diagnosed with advanced hepatocellular carcinoma began treatment with sorafenib. After 3 weeks of treatment, he complained of abdominal pain and nausea. Abdominal sonography showed multiple hepatic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
An Analysis for Survival Predictors for Patients with Hepatocellular Carcinoma Who Failed to Sorafenib Treatment in Pre-regorafenib Era

Lee CU, Lee YS, Kim JH, Lee M, Kim S, Jung YK, Seo YS, Yim HJ, Yeon JE, Byun KS

BACKGROUND/AIMS: Sorafenib is the standard treatment for patients with advanced hepatocellular carcinoma (HCC). We aimed to investigate the prognosis predictors and the role of second-line cytotoxic systemic chemotherapy (CSC) in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Serum PD-1 Levels Change with Immunotherapy Response but Do Not Predict Prognosis in Patients with Hepatocellular Carcinoma

Lee HW, Cho KJ, Shin SY, Kim HY, Lee EJ, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Han KH

BACKGROUND/AIMS: Programmed death receptor 1 (PD-1) is a promising new target for treatment of patients with hepatocellular carcinoma (HCC). A high expression level of programmed death-ligand 1 (PD-L1) is a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr